Shares of Kite Pharma (KITE) fell Monday due to the death of a cancer patient from brain swelling following treatment with the company's CAR-T therapy KTE-C19.
The patient death in a KTE-C19 safety study occurred in April. The FDA was notified but the study was not placed on any clinical hold, Kite said on a Monday morning conference call.
Still, the death rattled investors because death from brain swelling, or cerebral edema, is the same severe toxic event that scuttled a competing CAR-T therapy from Juno Therapeutics (JUNO) .
Kite shares are down 11% to $73.10 in Monday trading.
Until Monday's disclosure, Kite's KTE-C19 development program had not recorded a death due to cerebral edema. The FDA is currently reviewing an application submitted by Kite to approve KTE-C19 for patients with advanced non-Hodgkin lymphoma.
On its Monday call, Kite Chief Medical Officer David Chang said the patient who died had refractory non-Hodgkin lymphoma described as "explosive" and "rapidly progressing" before treatment with KTE-C19. Within two days, the patient's neurological condition deteriorated quickly, leading to death, Chang said.
CAR-T is a new form of cancer immunotherapy in which a patient's own T cells are removed and then engineered to identify and kill malignant blood cancer cells. CAR-T is highly effective at eliminating cancer cells in patients no longer responsive to previous treatments but it's also risky. CAR-Ts are known to cause a dangerous, immune system-related toxicity known as cytokine release syndrome.
Juno Therapeutics was forced to discontinue development of JCAR015 following the deaths of five patients due to cerebral edema.
- Carly Fiorina: This Is How to Fix Health Care in America
- Hertz Shareholders Could Feel Pain Today as Company Misses Earnings
- Jim Cramer: Nvidia Is a Great Company but Be Careful
- Jim Cramer Is Watching Disney's Earnings on Tuesday
- Market Recon: Worryingly, the Indices Seem to Be Almost Resting at Lofty Levels
- Walgreens Gives FTC Deadline on Rite Aid Ruling